阿司匹林作为多模式血栓预防方案在初次全髋与全膝关节置换术中的临床效果:6078例病例回顾
该研究基于前瞻性医院获得性血栓栓塞数据库,纳入2013年1月1日至2016年12月31日期间接受初次全髋和全膝关节置换术并使用阿司匹林作为延伸院外药物抗凝的6078例患者,评估其疗效、安全性及不良血栓栓塞事件发生率。结果显示术后90天内深静脉血栓和肺栓塞的主要结局发生率为1.11%,伤口感染、出血并发症、再入院率和死亡率与已发表的低分子肝素数据相当。结论表明阿司匹林作为多模式血栓预防方案的一部分,在预防静脉血栓栓塞方面有效且安全,且成本更低。
要点
- 6078例初次全髋和全膝关节置换术患者使用阿司匹林作为延伸院外药物抗凝,术后90天内深静脉血栓和肺栓塞发生率为1.11%。
- 伤口感染、出血并发症、再入院率和死亡率与已发表的低分子肝素数据相当。
- 阿司匹林作为多模式血栓预防方案的一部分,是有效且安全的方案,且成本更低。
核心结论
- 阿司匹林作为多模式血栓预防方案的一部分,在预防静脉血栓栓塞方面有效且安全,与低分子肝素相比具有成本优势。
研究设计与样本
- 数据提取自前瞻性医院获得性血栓栓塞数据库,研究期为2013年1月1日至2016年12月31日,共纳入6078例接受初次全髋和全膝关节置换术并以阿司匹林作为延伸血栓预防的患者。
主要发现
- 术后90天内深静脉血栓和肺栓塞的主要结局发生率为1.11%。
- 伤口感染、出血并发症、再入院率和死亡率的次要结局发生率与已发表的低分子肝素使用后结果相当。
临床怎么用
- 作者认为阿司匹林作为多模式血栓预防方案的一部分,是预防静脉血栓栓塞的有效且安全方案,且成本更低。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Venous thromboembolism is a serious complication after total hip and knee arthroplasty. There is still no consensus regarding the best mode of thromboprophylaxis after lower limb arthroplasty. The aim of this study was to ascertain the efficacy, safety profile, and rate of adverse thromboembolic events of aspirin as extended out-of-hospital pharmacological anticoagulation for elective primary total hip and knee arthroplasty patients and whether these rates were comparable with published data for low-molecular-weight heparin (LMWH). METHODS: Data were extracted from a prospective hospital-acquired thromboembolism database. The period of study was from January 1, 2013 to December 31, 2016, and a total of 6078 patients were treated with aspirin as extended thromboprophylaxis after primary total hip and knee arthroplasty. RESULTS: The primary outcome measure of deep vein thrombosis and pulmonary embolism within 90 days postoperatively was 1.11%. The secondary outcome rates of wound infection, bleeding complications, readmission rate, and mortality were comparable to published results after LMWH use. CONCLUSION: The results of this study clearly show that aspirin, as part of a multimodal thromboprophylactic regime, is an effective and safe regime in preventing venous thromboembolism with respect to risk of deep vein thrombosis or pulmonary embolism when compared to LMWH. It is a cheaper alternative to LMWH and has associated potential cost savings.
引用
- Ghosh A, Best AJ, Rudge SJ, et al. Clinical Effectiveness of Aspirin as Multimodal Thromboprophylaxis in Primary Total Hip and Knee Arthroplasty: A Review of 6078 Cases. J Arthroplasty. 2019. PMID: 30982759. doi:10.1016/j.arth.2019.03.021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。